263 related articles for article (PubMed ID: 4595319)
21. [Immunologic aspects of the treatment of melanoma].
Pawlowska EM
Pol Tyg Lek; 1977 Jun; 32(24):939-41. PubMed ID: 882435
[No Abstract] [Full Text] [Related]
22. Primary inoculation tuberculosis after immunotherapy for malignant melanoma with BCG vaccine.
Caplan SE; Kauffman CL
J Am Acad Dermatol; 1996 Nov; 35(5 Pt 1):783-5. PubMed ID: 8912582
[No Abstract] [Full Text] [Related]
23. [Immunotherapy of malignant melanomas].
Macher E
Haematol Blood Transfus; 1978; 21():285-91. PubMed ID: 738638
[No Abstract] [Full Text] [Related]
24. Immunologic defects in melanoma patients: lack of effect of BCG therapy.
Gersten MJ; Hadden EM; Kaplan MH; Pinsky CM; Armstrong D; Hadden JW
Clin Bull; 1977; 7(2):63-9. PubMed ID: 902403
[No Abstract] [Full Text] [Related]
25. Results of adjuvant BCG immunotherapy in malignant melanoma.
Wätzig V; Knopf B
Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
[TBL] [Abstract][Full Text] [Related]
26. [Cancer immunotherapy in dermatological view (author's transl)].
Lübbe D; Gstöttner R
Arch Geschwulstforsch; 1980; 50(2):182-5. PubMed ID: 7436703
[TBL] [Abstract][Full Text] [Related]
27. Mumps virus and BCG vaccine in metastatic melanoma.
Minton JP
Arch Surg; 1973 Apr; 106(4):503-6. PubMed ID: 4572347
[No Abstract] [Full Text] [Related]
28. Immunologic approaches to various types of cancer with the use of BCG and purified protein derivatives.
Klein E; Holtermann OA; Papermaster B; Milgrom H; Rosner D; Klein L; Walker MJ; Zbar B
Natl Cancer Inst Monogr; 1973 Dec; 39():229-42. PubMed ID: 4595323
[No Abstract] [Full Text] [Related]
29. Oral bacille Calmette Guérin immunostimulation in malignant melanoma.
MacGregor AB; Falk RE; Landi S; Ambus U; Langer B
Surg Gynecol Obstet; 1975 Nov; 141(5):747-54. PubMed ID: 1105837
[TBL] [Abstract][Full Text] [Related]
30. Intralesional BCG application in malignant melanoma.
Sopková B; Kolár V
Neoplasma; 1976; 23(4):421-6. PubMed ID: 794745
[TBL] [Abstract][Full Text] [Related]
31. [Immunotherapy of cancer with BCG].
Yamamura Y; Azuma I
Nihon Rinsho; 1974 Mar; 32(3):542-53. PubMed ID: 4603604
[No Abstract] [Full Text] [Related]
32. B.C.G. in malignant melanoma.
Baker MA; Taub RN
Lancet; 1973 May; 1(7812):1117-8. PubMed ID: 4122031
[No Abstract] [Full Text] [Related]
33. Histologic changes in the human skin melanoma after intratumorous treatment with BCG.
Svejda J; Mechl Z; Sopková B; Foukal T
Neoplasma; 1979; 26(2):215-21. PubMed ID: 471128
[TBL] [Abstract][Full Text] [Related]
34. BCG and cancer.
Bast RC; Zbar B; Borsos T; Rapp HJ
N Engl J Med; 1974 Jun; 290(26):1458-69. PubMed ID: 4598691
[No Abstract] [Full Text] [Related]
35. Immune response and non-specific immunotherapy in melanoma.
El-Domeiri AA
Ann R Coll Surg Engl; 1978 Mar; 60(2):117-20. PubMed ID: 637492
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant therapy of malignant melanoma.
Vosika GJ
Minn Med; 1979 Jul; 62(7):515-7. PubMed ID: 386072
[No Abstract] [Full Text] [Related]
37. The use of oral BCG in the treatment or metastatic malignant melanoma.
Pritchard KI; Cowan DH; Baker MA; Osoba D; Phillips RA; Clark DA
Med Pediatr Oncol; 1976; 2(2):173-81. PubMed ID: 785199
[TBL] [Abstract][Full Text] [Related]
38. Hepatic granulomas and other hepatic lesions associated with BCG immunotherapy for cancer.
Bodurtha A; Kim YH; Laucius JF; Donato RA; Mastrangelo MJ
Am J Clin Pathol; 1974 Jun; 61(6):747-52. PubMed ID: 4598826
[No Abstract] [Full Text] [Related]
39. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
Calbo L; Gorgone S; Palmeri R; Salibra M; Melita P
Chir Ital; 1983 Aug; 35(4):519-25. PubMed ID: 6680859
[TBL] [Abstract][Full Text] [Related]
40. [Unspecific immunological investigations in patients with malignant melanoma (author's transl)].
Knopf B; Wätzig V
Dermatol Monatsschr; 1982 Jan; 168(1):24-33. PubMed ID: 7044849
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
